# US 2016/0355596 A1 · Method of using antibody polypeptides that antagonize cd40 to treat ibd

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355596 A1
- Document ID: US20160355596A1
- Status: Published application
- Kind: A1
- Application number: 15/118,279
- Filed: 2015-03-09
- Published: 2016-12-08
- Earliest claimed: 2014-03-07
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Marek HONCZARENKO; Shah VAISHALI; Xiaoni LIU; Wendy L. TRIGONA; Rong SHI; Suzanne J. SUCHARD; Karen D. PRICE; Linda M. GUSTAVSON
- Web page: https://patentgrep.com/patent/US20160355596A1

## CPC

- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/02: without antiinflammatory effect
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/53: Hinge
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.

## Claims

### Claim 1

A method of treating an inflammatory bowel disease (IBD) in a human patient, the method comprising administering to the patient at least one dose of an antibody polypeptide comprising (1) a variable domain wherein the amino acid sequence of the variable domain comprises BMS3h-56-269 (SEQ ID NO: 1) or differs from the amino acid sequence of BMS3h-56-269 (SEQ ID NO: 1) by up to 5 amino acids and (2) a human Fc domain, and the dose is selected from 0.5 to 750 milligrams (mg) of the antibody polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration is sub-cutaneous and the dose is from 0.5 to 300 milligrams (mg) of the antibody polypeptide.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administration is sub-cutaneous and the dose is from 0.5, 3, 10, 30, 100, 150, or 300 mg of the antibody polypeptide.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administration is sub-cutaneous, the dose is from 150 to 300 mg of the antibody polypeptide, and the method comprises at least four iterations of the administering step.

### Claim 5 (depends on 1)

The method of claim 1, wherein the administration is intravenous and the dose is from 100 to 750 mg of the antibody polypeptide.

### Claim 6 (depends on 1)

The method of claim 1, wherein the administration is intravenous and the dose is selected from 100 or 750 mg of the antibody polypeptide.

### Claim 7 (depends on 1)

The method of claim 1, wherein the antibody polypeptide is administered in combination with an immunosuppressive/immunomodulatory and/or anti-inflammatory agent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody polypeptide and the immunosuppressive/immunomodulatory and/or anti-inflammatory agent are administered sequentially.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antibody polypeptide and the immunosuppressive/immunomodulatory and/or anti-inflammatory agent are administered simultaneously.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody polypeptide and the immunosuppressive/immunomodulatory and/or anti-inflammatory agent are formulated in a single composition.

### Claim 11 (depends on 1)

The method of claim 1, wherein the IBD is selected from the group consisting of: colitis, Crohn's disease and Behcet's disease.

### Claim 12 (depends on 11)

The method of claim 11, wherein the colitis is selected from the group consisting of ulcerative colitis, collagenous colitis, lymphocytic colitis, and diversion colitis.

### Claim 13 (depends on 1)

The method of claim 1, wherein the Fc domain comprises an amino acid sequence selected from SEQ ID NO: 4 or SEQ ID NO: 6.

### Claim 14 (depends on 1)

The method of claim 1, wherein the antibody polypeptide further comprises a linker selected from the group consisting of: SEQ ID NOS: 8-16.

### Claim 15 (depends on 1)

The method of claim 1, wherein the amino acid sequence of the variable domain comprises BMS3h-56-269 (SEQ ID NO: 1).

### Claim 16 (depends on 15)

The method of claim 15, wherein the Fc domain (region) comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 17 (depends on 1)

The method of claim 1, wherein the antibody polypeptide comprises the amino acid sequence of SEQ ID NO: 5.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody polypeptide is linked to one or more PEG polymers.

### Claim 19 (depends on 1)

A kit for treating an inflammatory bowel disease (IBD) in a human patient, the kit comprising:
(a) a dose of an antibody polypeptide comprising BMS3h-56-269-IgG4 Fc fusion polypeptide (SEQ ID NO: 5), and
(b) instructional material for using the antibody polypeptide in the method of claim 1.
